Compounds > 2,3-dicyanohydroquinone
Page last updated: 2024-12-07

2,3-dicyanohydroquinone

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID78467
SCHEMBL ID627326
MeSH IDM0097062

Synonyms (42)

Synonym
unii-ttr9y6yss8
2,3-dicyano-hydroquinone
2,3-dicyanobenzene-1,4-diol
phthalonitrile, 3,6-dihydroxy-
ttr9y6yss8 ,
ai3-18625
einecs 225-241-0
nsc 43554
nsc-43554
3,6-dihydroxyphthalodinitrile
2,3-dicyano-p-hydroquinone
1, 3,6-dihydroxy-
phthalonitrile,6-dihydroxy-
nsc43554
OPREA1_391102
2,6-dihydroxyphtalonitrile
inchi=1/c8h4n2o2/c9-3-5-6(4-10)8(12)2-1-7(5)11/h1-2,11-12
1,2-benzenedicarbonitrile, 3,6-dihydroxy-
3,6-dihydroxyphthalonitrile
4733-50-0
2,3-dicyanohydroquinone
2,3-dicyanohydroquinone, 98%
3,6-dihydroxybenzene-1,2-dicarbonitrile
STK060808
D1610
2,3-dicyano-1,4-hydroquinone
A827187
AKOS005387679
FT-0609588
SCHEMBL627326
AB01332962-02
dicyanohydroquinone
2,3-dicyano-4-hydroxy-phenol
3,6-dihydroxyphthalonitrile #
W-106075
DTXSID80197109
mfcd00001790
NCGC00340677-01
2,3-dicyanohydroquinone;2,3-dicyano-p-hydroquinone
BCP21662
AS-15691
3,6-dihydroxy-1,2-benzenedicarbonitrile
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (10)

TimeframeStudies, This Drug (%)All Drugs %
pre-19905 (50.00)18.7374
1990's3 (30.00)18.2507
2000's1 (10.00)29.6817
2010's1 (10.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 22.50

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index22.50 (24.57)
Research Supply Index2.40 (2.92)
Research Growth Index4.31 (4.65)
Search Engine Demand Index21.17 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (22.50)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other10 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
ammonium hydroxide
azane : Saturated acyclic nitrogen hydrides having the general formula NnHn+2.		1.9710azane;
gas molecular entity;
mononuclear parent hydride		EC 3.5.1.4 (amidase) inhibitor;
metabolite;
mouse metabolite;
neurotoxin;
NMR chemical shift reference compound;
nucleophilic reagent;
refrigerant
hydrogen carbonate
Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.. hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.		1.9710carbon oxoanioncofactor;
Escherichia coli metabolite;
human metabolite;
mouse metabolite;
Saccharomyces cerevisiae metabolite
erythrosine
Fluoresceins: A family of spiro(isobenzofuran-1(3H),9'-(9H)xanthen)-3-one derivatives. These are used as dyes, as indicators for various metals, and as fluorescent labels in immunoassays.		2.6630
meglumine
Meglumine: 1-Deoxy-1-(methylamino)-D-glucitol. A derivative of sorbitol in which the hydroxyl group in position 1 is replaced by a methylamino group. Often used in conjunction with iodinated organic compounds as contrast medium.. N-methylglucamine : A hexosamine that is D-glucitol in which the hydroxy group at position 1 is substituted by the nitrogen of a methylamino group. A crystalline base, it is used in preparing salts of certain acids for use as diagnostic radiopaque media, while its antimonate is used as an antiprotozoal in the treatment of leishmaniasis.		1.9710hexosamine;
secondary amino compound
2-naphthol
2-naphthol: RN given refers to parent cpd. 2-naphthol : A naphthol carrying a hydroxy group at position 2.. naphthols : Any hydroxynaphthalene derivative that has a single hydroxy substituent.		2.3820naphtholantinematodal drug;
genotoxin;
human urinary metabolite;
human xenobiotic metabolite;
mouse metabolite;
radical scavenger
hymecromone
Hymecromone: A coumarin derivative possessing properties as a spasmolytic, choleretic and light-protective agent. It is also used in ANALYTICAL CHEMISTRY TECHNIQUES for the determination of NITRIC ACID.		1.9610hydroxycoumarinantineoplastic agent;
hyaluronic acid synthesis inhibitor
4-acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic acid
4-Acetamido-4'-isothiocyanatostilbene-2,2'-disulfonic Acid: A non-penetrating amino reagent (commonly called SITS) which acts as an inhibitor of anion transport in erythrocytes and other cells.		1.9710stilbenoid
4,4'-diisothiocyanostilbene-2,2'-disulfonic acid
4,4'-Diisothiocyanostilbene-2,2'-Disulfonic Acid: An inhibitor of anion conductance including band 3-mediated anion transport.		1.9710
2',7'-bis(carboxyethyl)-5(6)-carboxyfluorescein
[no description available]		2.6630
ConditionIndicatedRelationship StrengthStudiesTrials
Carcinoma, Ehrlich Tumor
A transplantable, poorly differentiated malignant tumor which appeared originally as a spontaneous breast carcinoma in a mouse. It grows in both solid and ascitic forms.		01.9610
Acid-Base Imbalance
Disturbances in the ACID-BASE EQUILIBRIUM of the body.		01.9710
Leucocythaemia
[description not available]		01.9610
Leukemia
A progressive, malignant disease of the blood-forming organs, characterized by distorted proliferation and development of leukocytes and their precursors in the blood and bone marrow. Leukemias were originally termed acute or chronic based on life expectancy but now are classified according to cellular maturity. Acute leukemias consist of predominately immature cells; chronic leukemias are composed of more mature cells. (From The Merck Manual, 2006)		01.9610